GlaxoSmithKline News and Research

RSS

Global Strategy for Women's and Children's Health draws more than $40 billion in resources

Culminating a global summit on the Millennium Development Goals (MDGs), United Nations Secretary-General Ban Ki-moon and Heads of State and Government, along with the private sector, foundations, international organizations, civil society and research organizations, kicked off a concerted world-wide effort to save the lives of more than 16 million women and children.

23 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Delphi Genetics licences StabyExpress technology for production of protein vaccines to GSK

Delphi Genetics SA has announced today the signature of a licensing agreement with GlaxoSmithKline for the use of the patented StabyExpress technology for the production of protein vaccines for human use.

22 Sep 2010

Mylan obtains temporary restraining order against Apotex and GlaxoSmithKline

Mylan Inc. today obtained a temporary restraining order from the U.S. District Court for the District of New Jersey that prohibits Apotex from "using, offering to sell, selling or shipping or otherwise launching … or importing" all three strengths of a generic version of GlaxoSmithKline's Paxil CR, Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, 12.5 mg, 25 mg and 37.5 mg.

22 Sep 2010

Pazopanib drug reduces thyroid cancer progression: Study

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

18 Sep 2010

Contracting & Outsourcing 2010 Conference to feature presentations of pharma, biopharma outsourcing

On Sept. 23 and 24, the Hyatt Regency in New Brunswick, N.J. will host Contracting & Outsourcing 2010, the 9th annual Conference and Tabletop Exhibition held by Contract Pharma Magazine. This year's Conference will feature a keynote presentation by Mac Lynch, Vice President, Contract Manufacturing at Pfizer, covering Global Pharma Outsourcing Trends. Other speakers and panelists represent FDA, Johnson & Johnson, Roche/Genentech, Bristol-Myers Squibb, Merck, GlaxoSmithKline and more.

17 Sep 2010

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.

17 Sep 2010

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.

16 Sep 2010

ESMO honors three eminent cancer specialists for their contribution towards medical research

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy.

16 Sep 2010

ESMO honors eminent cancer specialists

15 Sep 2010

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

Genmab announces update in corporate strategy

Genmab A/S announced today an update to its corporate strategy. Today's strategy update represents a new beginning for Genmab where we acknowledge our successes and learn from our mistakes.

14 Sep 2010

iPierian raises $28 million from Series B equity financing closure

iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the second closing of its Series B equity financing, bringing the total amount raised in this round to $28 million.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Wall Street Journal reports on pharma's growing interest in emerging markets

Abbott Laboratories will soon acquire the biggest share of India's pharmaceuticals market, about 7%, when the company closes as early as next month on a $3.7 billion takeover of the drugs business of Piramal Healthcare Ltd

27 Aug 2010

Specific type of neurons determine frightening stimulus reaction: Research

Fear can make you run, it can make you fight, and it can glue you to the spot. Scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy and GlaxoSmithKline in Verona, Italy, have identified not only the part of the brain but the specific type of neurons that determine how mice react to a frightening stimulus.

26 Aug 2010

Two diabetes medications increase risk of heart attack, failure: Study

In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same about 4 percent for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

25 Aug 2010

Survey finds women interested in human papillomavirus vaccination

Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.

25 Aug 2010

GlaxoSmithKline News and Research

Global Strategy for Women's and Children's Health draws more than $40 billion in resources

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Delphi Genetics licences StabyExpress technology for production of protein vaccines to GSK

Mylan obtains temporary restraining order against Apotex and GlaxoSmithKline

Pazopanib drug reduces thyroid cancer progression: Study

Contracting & Outsourcing 2010 Conference to feature presentations of pharma, biopharma outsourcing

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

ESMO honors three eminent cancer specialists for their contribution towards medical research

ESMO honors eminent cancer specialists

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Genmab announces update in corporate strategy

iPierian raises $28 million from Series B equity financing closure

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

FDA extends Prescription Drug User Fee Act date for ezogabine

Wall Street Journal reports on pharma's growing interest in emerging markets

Specific type of neurons determine frightening stimulus reaction: Research

Two diabetes medications increase risk of heart attack, failure: Study

Survey finds women interested in human papillomavirus vaccination

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News